SUMMARY Minigastrin, a gastrin with 13 amino-acid residues, was recently isolated from tissues by Gregory and Tracy (1974) . In this study, pure human natural nonsulphated minigastrin (HG-13-I) and pure human natural nonsulphated heptadecapeptide gastrin (HG-17-I) were compared with regard to acid-stimulating potency and rate of disappearance from blood. Three dogs with gastric fistulae and Heidenhain pouches were given these gastrins by continuous intravenous infusion in doses of 100, 200, 400, and 800 pmol/kg-hr. Equimolar infusion rates of HG-13-I and HG-17-I caused equimolar increases over basal of serum immunoreactive gastrin but HG-1 3-I-was less than half as potent as HG-17-I in stimulating acid secretion (potency ratio 0.4, 950% confidence limits 0.2 to 0.6). The half time for disappearance of HG-13-I from blood was 1.8 minutes and its volume of distribution was calculated to be 0.17 1/kg, values similar to those found for HG-17-I in an earlier study. The role of minigastrin in health and disease awaits further study.
Minigastrin, a gastrin with 13 amino acid residues corresponding to the carboxy-terminal part of the larger gastrins, has been isolated in both sulphated and nonsulphated forms from gastrinomas by Gregory and Tracy (1974) . On gel ffitration of human serum on Sephadex G-50 an immunoreactive component with the same elution volume as minigastrin has been found by Rehfeld and Stadil (1973) , thus suggesting that minigastrin is one of the circulating forms of gastrin.
We (Walsh, Debas, and Grossman, 1974a) have proposed that the gastrins of known structure be designated by the number of amino-acid residues they contain, by their species of origin, and by the presence (II) or absence (I) of sulphation of the tyrosine residue. Thus nonsulphated human minigastrin, the subject of this study, would be designated HG-1 3-1.
The purpose of this study is to compare HG-13-I and HG-17-I with respect to gastric acid stimulation and rates of disappearance from the circulation. 
90073.
Received for publication 29 May 1974 fessor R. A. Gregory and Dr H. J. Tracy, University of Liverpool, who prepared them from a gastrinsecreting tumour of the Zollinger-Ellison variety (Gregory and Tracy, 1974) . The gastrins were dissolved in 0.1 M NH40H in concentrations of about 50 nmol/ml. The molar concentration of gastrin in the solutions was calculated by dividing the absorbence at 280 nm by the extinction coefficient calculated (Wetlaufer, 1962) as the sum of the products of the number of residues of tryptophan and tyrosine per molecule times the respective extinction coefficients of these amino acids (Mihalyi, 1968 Two basal blood samples, 15 minutes apart, were obtained before starting gastrin infusions. Blood samples were taken 15 and 25 minutes after the start of the infusion of each dose of gastrin. Serum was separated and stored at -20°C. The gastrin concentration in all samples was measured by radioimmunoassay as previously described (Stern and Walsh, 1973) . The antibody used for these assays was no. 1296 (Walsh, Trout, Debas, and Grossman, 1974b) .
In preliminary studies, the immunoreactivity of HG-13-I was found to be 60% of that of HG-17-I. This difference in immunoreactivity did not affect the measurements because serum gastrin for each test was expressed in terms of a standard made from the gastrin infused in that test.
For the half-time studies, HG-13-1 was infused into seven dogs at a dose of 1000 pmol/kg-hr for 20 minutes. Blood samples were taken before the start of the infusion, at 10, 18, and 20 min after starting the infusion, and every two min after the infusion was stopped until acid secretion returned to basal levels. Basal The volume of distribution was calculated by the use of the plateau principle described by Goldstein, Aronow, and Kalman (1968) from the equation V = D/Gk where V is the volume of distribution in 1/kg, D is the dose of gastrin in pmol/kg-min, G is the plateau serum gastrin in pmol/1, and k is the rate constant described above.
Clearance did not fit the Michaelis-Menten model satisfactorily, the comparison of potency was made by using the 3 + 3 dose parallel line assay (Colquhoun, 1971 caused similar molar increases over basal in serum immunoreactive gastrin (table II) . Basal gastrin, which has been shown to be mainly 'big-big' (Yalow and Wu, 1973) , was subtracted from each value on the reasonable assumption that neither its molecular form nor its amount changes during the infusion period. The increment in serum gastrin was linearly related to the dose of gastrin for both HG-13-I and HG-17-I and the slopes of these lines did not differ (table II) . The linear relation between dose and plateau serum level indicates that the rate of disposal of these gastrins did not vary with dose over the dose range studied. The similarity of the slopes for the two gastrins indicates that they have similar rates of disposal.
CLEARANCE RATES
Clearance rates, calculated by dividing the dose infused by the plateau blood level of gastrin, were similar for the two gastrins. The mean value for HG-13-I was 79 ml/kg-min and for HG-17-I it was 83 ml/kg-min (table I) .
SERUM GASTRIN HALF-TIME HG-13-I was rapidly removed from the circulation and was virtually undetectable six to eight min after stopping the infusion (figure 2). The calculated halftime was 1.75 minutes.
Discussion
Minigastrin is the latest member of the growing family of gastrins (Rehfeld, 1973) : 'little' gastrin (17 amino-acid residues), 'big' gastrin (33 aminoacid residues), and 'big-big' gastrin and 'component I' whose structures are still to be determined. Structurally minigastrin is heptadecapeptide gastrin without the N-terminal tetrapeptide. Gregory and Tracy (1974) have recently isolated the sulphated and nonsulphated forms of minigastrin in pure form from gastrinoma tissue. Rehfeld and Stadil (1973) , in gel filtration studies of immunoreactive gastrin in serum from patients with gastrinomas, found a pair of small presalt peaks with elution volumes similar to those of the minigastrins. This study has shown that HG-13-I is less than half as potent as HG-17-I in its ability to stimulate gastric acid secretion. Since equal rates of infusion of the two gastrins cause equal increments in serum gastrin, the lower potency of HG-13-I is equally apparent whether one defines 'potency' in terms of exogenous dose or of serum concentration, ie, 'endogenous dose'. A strikingly different set of relationships exists when HG-17-I is compared with human nonsulphated big gastrin (HG-34-I) (Walsh et al, 1974a) . In the latter case, while HG-17-I and HG-34-I appear to have similar potencies when only exogenous doses are considered, HG-17-I is five times more potent when circulating concentrations are compared. This is so because when these two gastrins are infused at equimolar rates, HG-34-I achieves a much higher increment in serum concentration owing to the slow rate of its elimination from the circulation. These observations indicate the need for circumspect interpretations of total serum gastrin concentrations and underscore the potential usefulness of antibodies with specificity for the various molecular forms of gastrin. Only when we can readily measure the different gastrin fractions in the serum will we be able to compare meaningfully serum gastrin levels with acid secretion.
The half-time for disappearance of immunoreactivity from serum was 1P75 min for HG-13-I from the present study and 2-9 mim for HG-17-I from an earlier study (Walsh et al, 1974a) . Similarly the space of distribution was 017 1/kg for HG-13-I in the present study and 024 1/kg for HG-17-I from the same earlier study. Since the overall disposal rate as reflected in the plateau serum level was the same for HG-13-I and HG-17-I in the present study (table I) , we think that these differences in calculated half-times and spaces of distribution are probably not significant but a study designed to compare them in the same animals would be needed to settle the question. There are many unanswered questions about the different molecular forms of gastrin. Are they synthesized as separate molecules, or is only the biggest molecule synthesized and enzymatic degradation generates the smaller forms? If the latter is true, what activates the enzymatic process and does it take place in the cytoplasm or at the cell membrane? Are there selective mechanisms of release for individual types of gastrin? Are the relative potencies of the individual gastrins the same at various target organs? When 'little' or 'big' gastrin is infused into the circulation, is there conversion to 'minigastrin'? One predictable result of the discovery of these various species of gastrin will be to stimulate further basic and applied investigation.
